Open AccessMultisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ( 18 F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer
Author(s) -
Tore BachGansmo,
Cristinni,
Peter T. Nieh,
Lucia Zai,
Tronde Velde Bogsrud,
Heidi Sletten,
Katrine Andersen Korsan,
Jesse Kieboom,
Funmilayo Tade,
Oluwaseun Odewole,
Albert Chau,
Penelope Ward,
Mark M. Goodman,
Stefano Fanti,
David M. Schuster,
Frode Willoch
Publication year - 2017
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1016/j.juro.2016.09.117
Subject(s) - medicine , positron emission tomography , tomography , prostate cancer , nuclear medicine , radiology , medical physics , positron emission tomography computed tomography , cancer
Sensitive detection of cancer foci in men experiencing biochemical recurrence following initial treatment of prostate cancer is of great clinical significance with a possible impact on subsequent treatment choice. We describe a multisite experience of the efficacy and safety of the positron emission tomography/computerized tomography agent fluciclovine ( 18 F) after biochemical recurrence.